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The recently published MM-WES study (Medco-Mayo Warfarin
Effectiveness Study) (1) addresses an urgent need for evidence
in the area of pharmacogenomics, in this case the potential
impact on clinical outcomes of pharmacogenetic testing for
guiding warfarin dosing. However, serious design flaws preclude
drawing reliable conclusions from this study. Modest changes in
the original study design would have produced more convincing
results.
A major concern is selection bias arising from the use of a
historical control group. Outcomes such as hospital stays might be
more strongly influenced by clinical and demographic characteris-
tics and their variable distribution between groups than by genetic
testing. Unfortunately, because key information such as the num-
ber of patients who were offered enrollment but declined was
omitted, it is impossible to exclude the possibility that the results
are heavily influenced by selection bias. A high patient refusal rate
could produce a highly selected population, not comparable to
unselected historical controls. Often patients who agree to enroll in
trials are healthier than those who do not agree, the so-called
“healthy volunteer” effect (2,3).
Even for the limited set of baseline clinical and demographic
variables examined, there were differences between intervention
and control groups in the history of hypertension and history of
diabetes. The same limited set of factors was used for propensity
matching, making it unlikely that baseline differences could be
controlled. Important potential confounders such as ethnicity,
socioeconomic status, and educational level—which are often
powerful predictors of whether a patient agrees to enter the study
and whether the patient is hospitalized—were not available.
Strong clues in these data suggest that outcome differences
might be heavily influenced by factors other than genetic testing.
Hospital stays related to bleeding/thromboembolism were reduced
by 2.16% in absolute terms (from 8.13% to 5.97%), whereas
all-cause hospital stays had a much larger reduction of 7.07% (from
25.52% to 18.45%). This is more than triple the absolute effect that
would be expected from an improvement in hospital stays for
bleeding/thromboembolism resulting from genetic testing. The
authors do not provide an explanation for this large difference
(4.91%) in hospital stays that are not for hematologic reasons. In
addition, an increase in the difference between groups over time
(Fig. 1 in Epstein et al. [1])—indicating an increase in the absolute
effect—is not expected, because most of the benefit of testing
should be seen early.
Nonrandomized study designs must be used in situations where
randomized controlled trials (RCTs) are either not feasible or
unethical. That is not the case for this clinical question. At least 2
RCTs are already underway, as noted in the accompanying
editorial by Ginsburg and Voora (4). Moreover, this study could
have been conducted as an RCT simply by sending the test results
randomly to one-half of the physicians caring for patients tested.This would have eliminated selection bias while preserving the
“naturalistic setting” (1) and the advantage of improved general-
izability. Because of these limitations, the results of this study need
to be validated in an RCT before we can conclude that genetic
testing for warfarin dosing confers clinical benefits.
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Reply
Dr. Lefevre and colleagues express concern about selection bias in
our study due to low patient acceptance rates (1), a concern also
expressed by Ginsburg and Voora in their accompanying editorial
(2). In fact, 46% of subjects contacted agreed to participate. We
compared subjects declining to participate with subjects agreeing
to participate on 29 baseline variables. Participating subjects had
more prior use of nonsteroidal anti-inflammatory drugs (19.9% vs.
15.4%) and more frequent prior history of gastrointestinal bleed
(4.0% vs. 2.2%), suggesting that participants would have biased
against our findings, because participants were at a slightly higher
risk of adverse outcomes compared with nonparticipants.
The concerns Dr. Lefevre and colleagues have expressed about
potential confounders such as socioeconomic status, ethnicity, and
educational level were addressed in the study design. Both the
intervention group and the control group were derived from the
same participating payer organizations. Therefore, both groups
had the same insurance coverage and access to care. Additionally,
because both groups were constructed from the same payer
organizations in the same regions and from the same industries, it
is reasonable to assume they were similar in socioeconomic status
and in other unmeasured factors as well.
The larger difference we showed in “all-cause” hospital stay
compared with bleeds or thromboembolic events was anticipated
and expected. Prior studies describe imprecision inherent in
International Classification of Diseases of the World Health
Organization-9th Edition claims coding. We used validated codes
